Spruce Biosciences, Inc. (SPRB) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1243142,
    "name": "Spruce Biosciences, Inc.",
    "stock_name": "Spruce Biosciences, Inc.",
    "full_name": "Spruce Biosciences, Inc.",
    "name_url": "stocks-analysis/spruce-biosciences-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "90.44",
    "chg": 1.24,
    "chgp": "1.39%",
    "dir": 1,
    "prev_price": "89.20",
    "mcapval": "5.07",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2320,
    "indexname": "S&P 500",
    "isin": "US85209E1091",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "95.42 k",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/spruce-biosciences-inc-1243142-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is Spruce Biosciences, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-spruce-biosciences-inc-technically-bullish-or-bearish-3547838",
        "imagepath": "",
        "date": "2025-09-20 20:04:10",
        "description": "As of 5 September 2025, the technical trend for Spruce Biosciences, Inc. has changed from mildly bullish to bullish. The current stance is bullish, with key indicators supporting this view including a bullish monthly RSI and a bullish weekly KST. However, the daily moving averages indicate a mildly bearish trend, which suggests some short-term weakness. \n\nIn terms of multi-period returns, the stock has significantly underperformed compared to the S&P 500, with a year-to-date return of -71.8% versus the S&P's 12.22%, and a one-year return of -73.54% compared to the S&P's 17.14%...."
      },
      {
        "title": "Is Spruce Biosciences, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-spruce-biosciences-inc-overvalued-or-undervalued-3544085",
        "imagepath": "",
        "date": "2025-09-20 18:37:17",
        "description": "As of 15 May 2023, the valuation grade for Spruce Biosciences, Inc. has moved from does not qualify to risky, indicating increased uncertainty regarding its valuation. The company appears to be overvalued, particularly given its low Price to Book Value of 0.18 and an EV to EBITDA ratio of 0.37, which suggests that investors are paying a premium relative to its earnings potential. Additionally, the ROCE stands at an impressive 670.25%, yet the negative ROE of -361.86% raises concerns about profitability and financial health.\n\nIn comparison to its peers, Spruce Biosciences has a P/E ratio that is not applicable due to its loss-making status, while CARA Therapeutics, Inc. has a P/E of -9.4978 and NGM Biopharmaceuticals, Inc. shows a P/E of -0.9351, highlighting the challenging environment for these companies. Over the past year, Spruce Biosciences has significantly underperformed, with a stock return of -73.54..."
      }
    ],
    "total": 7,
    "sid": "1243142",
    "stock_news_url": "https://www.marketsmojo.com/news/spruce-biosciences-inc-1243142"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Is Spruce Biosciences, Inc. technically bullish or bearish?

2025-09-20 20:04:10

As of 5 September 2025, the technical trend for Spruce Biosciences, Inc. has changed from mildly bullish to bullish. The current stance is bullish, with key indicators supporting this view including a bullish monthly RSI and a bullish weekly KST. However, the daily moving averages indicate a mildly bearish trend, which suggests some short-term weakness. In terms of multi-period returns, the stock has significantly underperformed compared to the S&P 500, with a year-to-date return of -71.8% versus the S&P's 12.22%, and a one-year return of -73.54% compared to the S&P's 17.14%....

Is Spruce Biosciences, Inc. overvalued or undervalued?

2025-09-20 18:37:17

As of 15 May 2023, the valuation grade for Spruce Biosciences, Inc. has moved from does not qualify to risky, indicating increased uncertainty regarding its valuation. The company appears to be overvalued, particularly given its low Price to Book Value of 0.18 and an EV to EBITDA ratio of 0.37, which suggests that investors are paying a premium relative to its earnings potential. Additionally, the ROCE stands at an impressive 670.25%, yet the negative ROE of -361.86% raises concerns about profitability and financial health. In comparison to its peers, Spruce Biosciences has a P/E ratio that is not applicable due to its loss-making status, while CARA Therapeutics, Inc. has a P/E of -9.4978 and NGM Biopharmaceuticals, Inc. shows a P/E of -0.9351, highlighting the challenging environment for these companies. Over the past year, Spruce Biosciences has significantly underperformed, with a stock return of -73.54...

View All News